secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2026-09-09T11:30:47+00:00
Accession:  0001140361-26-035979
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Opus Genetics reports positive Cohort 1 data for OPGx-BEST1; FDA aligns on pivotal endpoint
--------------------------------------------------------------------------------

- All 5 Cohort 1 participants showed clinically meaningful visual function improvement; BCVA improved in 3/5, microperimetry in 3/4 evaluable.
- No serious adverse events or dose-limiting toxicities; structural improvements in 4/5, including vitelliform reduction in 2/3 BVMD.
- FDA aligned on ≥3 dB microperimetry improvement in ≥5 loci with patient-reported outcome as potential pivotal endpoint.
- Cohort 2 over-enrolled to 8 participants; dosing complete Q4 2026, topline data Q2 2027; cash runway into 2029.
- New epidemiology estimates ~23,600 symptomatic BEST1 patients in US and ~45,400 globally.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036126035979/0001140361-26-035979-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036126035979/ef20081753_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-035979

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer